SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition

(2015) Anne L. Peters et al.   DIABETES CARE

SGLT2 Inhibitors May Predispose to Ketoacidosis

(2015) Simeon I. Taylor et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study

(2014) Kohei Kaku et al.   Cardiovascular Diabetology

Dapagliflozin as Monotherapy in Drug-Naive Asian Patients With Type 2 Diabetes Mellitus: A Randomized, Blinded, Prospective Phase III Study

(2014) Linong Ji et al.   CLINICAL THERAPEUTICS

Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study

(2014) Yutaka Seino et al.   CURRENT MEDICAL RESEARCH AND OPINION

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

(2014) Hans-Ulrich Häring et al.   DIABETES CARE

Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study

(2014) A. Kashiwagi et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study

(2014) Nobuya Inagaki et al.   EXPERT OPINION ON PHARMACOTHERAPY

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial

(2014) Peter Stein et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers

(2013) Jeroen P Jansen et al.   BMC Medicine

Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study

(2013) D. Polidori et al.   DIABETES CARE

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

(2013) F. J. Lavalle-González et al.   DIABETOLOGIA

Evaluation of inconsistency in networks of interventions

(2013) A. A. Veroniki et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Bayesian Network Meta-Analysis to Assess Relative Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled with Metformin

(2013) M. Pacou et al.   VALUE IN HEALTH

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

(2013) Michael Roden et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial

(2012) K. Kaku et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

(2012) K. Stenlöf et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

(2012) R. R. Henry et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

(2012) Jan Bolinder et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies

(2012) J. P. T. Higgins et al.   Research Synthesis Methods

How Valuable are Multiple Treatment Comparison Methods in Evidence-Based Health-Care Evaluation?

(2011) Nicola J. Cooper et al.   VALUE IN HEALTH

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial

(2010) E. Ferrannini et al.   DIABETES CARE

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

(2010) Clifford J Bailey et al.   LANCET

Checking consistency in mixed treatment comparison meta-analysis

(2010) S. Dias et al.   STATISTICS IN MEDICINE